FDA approves first artificial iris

FDA approves first artificial iris

(HealthDay)—The first artificial iris has been approved by the U.S. Food and Drug Administration for patients with aniridia.

The CustomFlex Artificial Iris is custom-colored and molded for each user from medical-grade silicone. The device was evaluated in involving almost 400 adults and children. More than 70 percent of users reported decreased and glare, and 94 percent of users were satisfied with the device's appearance, the FDA said.

The most common side effects included device movement or dislocation, increased , iritis, synechiae, and the need for additional surgery to reposition, remove, or replace the device. The device isn't recommended for pregnant women or for people with certain medical conditions affecting the eye, the agency said.

"Patients with iris defects may experience severe vision problems, as well as dissatisfaction with the appearance of their eye," Malvina Eydelman, M.D., director of the Division of Ophthalmic, and Ear, Nose and Throat Devices at the FDA's Center for Devices and Radiological Health, said in a statement. "Today's approval of the first artificial iris provides a novel method to treat iris defects that reduces sensitivity to bright light and glare. It also improves the cosmetic appearance of the eye in patients with aniridia."

The CustomFlex Artificial Iris is produced by the German firm HumanOptics AG.


Explore further

US approves artificial-intelligence device for diabetic eye problems

More information: More Information

Copyright © 2018 HealthDay. All rights reserved.

Citation: FDA approves first artificial iris (2018, June 1) retrieved 23 September 2019 from https://phys.org/news/2018-06-fda-artificial-iris.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
30 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more